NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Replying to myself to expand on the topic of combo therapies…

Just to clarify: I did not mean to suggest that pexidartinib (PLX3397) is an ADC. CSF-1R inhibitors and Antibody Drug Conjugates (ADCs) are distinct types of therapies.

I’m just beginning to research this topic and I am interested in learning more about the potential for combining DCVax-L with other immunotherapy agents beyond only PD-1 blockade. The Merck deal with Daiichi Sankyo has cast some light on fascinating new possibilities…

From my research:

“CSF-1R inhibitors target the Colony-Stimulating Factor 1 Receptor, often involved in regulating the immune system. On the other hand, ADCs are a type of targeted therapy that combines an antibody with a drug payload.”

https://www.daiichisankyo.com/products/